Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer

Ads

You May Also Like

Biocartis Group NV: BIOCARTIS Q3 2018 BUSINESS UPDATE

PRESS RELEASE: REGULATED INFORMATION Thursday, 15 November 2018, 07:00 CET BIOCARTIS Q3 2018 BUSINESS ...

ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring

SINGAPORE, Jan. 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused ...